A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder.

Trial Profile

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2014 Results published in the International Clinical Psychopharmacology.
    • 14 Mar 2013 Primary endpoint 'Hamilton-Depression-Rating-Scale' has not been met.
    • 07 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top